|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Medical Research Council Oesophageal
Cancer Working Group, : Surgical resection with or without
preoperative chemotherapy in oesophageal cancer: A randomised
controlled trial. Lancet. 359:1727–1733. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Allum WH, Stenning SP, Bancewicz J, Clark
PI and Langley RE: Long-term results of a randomized trial of
surgery with or without preoperative chemotherapy in esophageal
cancer. J Clin Oncol. 27:5062–5067. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ando N, Kato H, Igaki H, Shinoda M, Ozawa
S, Shimizu H, Nakamura T, Yabusaki H, Aoyama N, Kurita A, et al: A
randomized trial comparing postoperative adjuvant chemotherapy with
cisplatin and 5-fluorouracil versus preoperative chemotherapy for
localized advanced squamous cell carcinoma of the thoracic
esophagus (JCOG9907). Ann Surg Oncol. 19:68–74. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yamasaki M, Yasuda T, Yano M, Hirao M,
Kobayashi K, Fujitani K, Tamura S, Kimura Y, Miyata H, Motoori M,
et al: Multicenter randomized phase II study of cisplatin and
fluorouracil plus docetaxel (DCF) compared with cisplatin and
fluorouracil plus adriamycin (ACF) as preoperative chemotherapy for
resectable esophageal squamous cell carcinoma (OGSG1003). Ann
Oncol. 28:116–120. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shiraishi O, Yamasaki M, Makino T, Motoori
M, Miyata H, Shinkai M, Kimura Y, Hirao M, Fujitani K, Tamura S, et
al: Feasibility of preoperative chemotherapy with docetaxel,
cisplatin, and 5-fluorouracil versus adriamycin, cisplatin, and
5-fluorouracil for resectable advanced esophageal cancer. Oncology.
92:101–108. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shimakawa T, Naritaka Y, Asaka S, Isohata
N, Murayama M, Konno S, Yoshimatsu K, Shiozawa S, Katsube T and
Ogawa K: Neoadjuvant chemotherapy (FAP) for advanced esophageal
cancer. Anticancer Res. 28:2321–2326. 2008.PubMed/NCBI
|
|
8
|
Motoori M, Yano M, Yasuda T, Miyata H,
Peng YF, Yamasaki M, Shiraishi O, Masuzawa Y, Tanaka K, Ishikawa O,
et al: Chemotherapy-induced toxicities and treatment efficacy in
advanced esophageal cancer treated with neoadjuvant chemotherapy
followed by surgery. Esophagus. 8:81–87. 2011. View Article : Google Scholar
|
|
9
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
McMillan DC: Systemic inflammation,
nutritional status and survival in patients with cancer. Curr Opin
Clin Nutr Metab Care. 12:223–226. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang W, Wang S, Zhang H, Zhang B and Wang
C: Prognostic significance of combined fibrinogen concentration and
neutrophil-to-lymphocyte ratio in patients with resectable
non-small cell lung cancer. Cancer Biol Med. 15:88–96. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Y, Jiang C, Li J, Sun J and Qu X:
Prognostic significance of preoperative neutrophil/lymphocyte ratio
and platelet/lymphocyte ratio in Patients with gallbladder
carcinoma. Clin Transl Oncol. 17:810–818. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huszno J and Kolosza Z: Prognostic value
of the neutrophil-lymphocyte, platelet-lymphocyte and
monocyte-lymphocyte ratio in breast cancer patients. Oncol Lett.
18:6275–6283. 2019.PubMed/NCBI
|
|
14
|
Sharaiha RZ, Halazun KJ, Mirza F, Port JL,
Lee PC, Neugut AI, Altorki NK and Abrams JA: Elevated preoperative
neutrophil: Lymphocyte ratio as a predictor of postoperative
disease recurrence in esophageal cancer. Ann Surg Oncol.
18:3362–3369. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen L, Zeng H, Yang J, Lu Y, Zhang D,
Wang J, Kuang C, Zhu S, Wang M and Ma X: Survival and prognostic
analysis of preoperative inflammatory markers in patients
undergoing surgical resection for laryngeal squamous cell
carcinoma. BMC Cancer. 18:8162018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yamasaki M, Miyata H, Tanaka K, Shiraishi
O, Motoori M, Peng YF, Yasuda T, Yano M, Shiozaki H, Mori M and
Doki Y: Multicenter phase I/II study of docetaxel, cisplatin and
fluorouracil combination chemotherapy in patients with advanced or
recurrent squamous cell carcinoma of the esophagus. Oncology.
80:307–313. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu T and Dai Y: Tumor microenvironment and
therapeutic response. Cancer Lett. 387:61–68. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hoshino S, Takeuchi M, Kawakubo H,
Kobayashi R, Matsuda S, Irino T, Fukuda K, Nakamura R and Kitagawa
Y: Neutrophil-to-lymphocyte ratio change predicts histological
response to and oncological outcome of neoadjuvant chemotherapy for
esophageal squamous cell carcinoma. Esophagus. 19:426–435. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sobin LH, Gospodarowicz MK and Wittekind
C: UICC International Union Against Cancer. TNM classification of
malignant tumors. 7th edition. New York: Wiley-Blackwell; 2009
|
|
20
|
Japan Esophageal Society: Japanese
classification of esophageal cancer, 11th edition: Part II and III.
Esophagus. 14:37–65. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
National Cancer Institute, . Common
terminology criteria for adverse events (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
|
|
22
|
Yano M, Takachi K, Doki Y, Miyashiro I,
Kishi K, Noura S, Eguchi H, Yamada T, Ohue M, Ohigashi H, et al:
Preoperative chemotherapy for clinically node-positive patients
with squamous cell carcinoma of the esophagus. Dis Esophagus.
19:158–163. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kitagawa Y, Uno T, Oyama T, Kato K, Kato
H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, et al:
Esophageal cancer practice guidelines 2017 edited by the Japan
esophageal society: Part 2. Esophagus. 16:25–43. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yamashita K, Makino T, Yamasaki M, Tanaka
K, Hara T, Miyazaki Y, Takahashi T, Kurokawa Y, Nakajima K,
Takiguchi S, et al: Comparison of short-term outcomes between 2-
and 3-field lymph node dissection for esophageal cancer. Dis
Esophagus. 30:1–8. 2017. View Article : Google Scholar
|
|
25
|
Toh Y, Kitagawa Y, Kuwano H, Kusano M,
Oyama T, Muto M, Kato H, Takeuchi H, Doki Y, Naomoto Y, et al: A
nation-wide survey of follow-up strategies for esophageal cancer
patients after a curative esophagectomy or a complete Response by
definitive chemoradiotherapy in Japan. Esophagus. 13:173–181. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yodying H, Matsuda A, Miyashita M,
Matsumoto S, Sakurazawa N, Yamada M and Uchida E: Prognostic
significance of neutrophil-to-lymphocyte ratio and
platelet-to-lymphocyte ratio in oncologic outcomes of esophageal
cancer: A systematic review and meta-analysis. Ann Surg Oncol.
23:646–654. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pirozzolo G, Gisbertz SS, Castoro C, van
Berge Henegouwen MI and Scarpa M: Neutrophil-to-lymphocyte ratio as
prognostic marker in esophageal cancer: A systematic review and
meta-analysis. J Thorac Dis. 11:3136–3145. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Miyazaki T, Sakai M, Sohda M, Tanaka N,
Yokobori T, Motegi Y, Nakajima M, Fukuchi M, Kato H and Kuwano H:
Prognostic significance of inflammatory and nutritional parameters
in patients with esophageal cancer. Anticancer Res. 36:6557–6562.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang L, Wang C, Wang J, Huang X and Cheng
Y: A novel systemic immune-inflammation index predicts survival and
quality of life of patients after curative resection for esophageal
squamous cell carcinoma. J Cancer Res Clin Oncol. 143:2077–2086.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ishibashi Y, Tsujimoto H, Hiraki S, Kumano
I, Yaguchi Y, Horiguchi H, Nomura S, Ito N, Shinto E, Aosasa S, et
al: Prognostic value of preoperative systemic immunoinflammatory
measures in patients with esophageal cancer. Ann Surg Oncol.
25:3288–3299. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu XL, Yu HQ, Hu W, Song Q and Mao WM: A
novel inflammation-based prognostic score, the C-reactive
protein/albumin ratio predicts the prognosis of patients with
operable esophageal squamous cell carcinoma. PLoS One.
10:e01386572015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee Y, Kim SH, Han JY, Kim HT, Yun T and
Lee JS: Early neutrophil-to-lymphocyte ratio reduction as a
surrogate marker of prognosis in never smokers with advanced lung
adenocarcinoma receiving gefitinib or standard chemotherapy as
first-line therapy. J Cancer Res Clin Oncol. 138:2009–2016. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Coussens LM and Werb Z: Inflammatory cells
and cancer: Think different! J Exp Med. 193:F23–F26. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cassatella MA: Neutrophil-derived
proteins: Selling cytokines by the pound. Adv Immunol. 73:369–509.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Scapini P, Bazzoni F and Cassatella MA:
Regulation of B-cell-activating factor (BAFF)/B lymphocyte
stimulator (BLyS) expression in human neutrophils. Immunol Lett.
116:1–6. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jabłońska E, Wawrusiewicz-Kurylonek N,
Garley M, Ratajczak-Wrona W, Antonowicz B, Dziemiańczyk-Pakieła D,
Jabłoński J, Krętowski A and Grabowska SZ: A proliferation-inducing
ligand (APRIL) in neutrophils of patients with oral cavity squamous
cell carcinoma. Eur Cytokine Netw. 23:93–100. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ogiya R, Niikura N, Kumaki N, Bianchini G,
Kitano S, Iwamoto T, Hayashi N, Yokoyama K, Oshitanai R, Terao M,
et al: Comparison of tumor-infiltrating lymphocytes between primary
and metastatic tumors in breast cancer patients. Cancer Sci.
107:1730–1735. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hagi T, Makino T, Yamasaki M, Tanaka K,
Nishida N, Sakai D, Motoori M, Kimura Y, Satoh T, Mori M and Doki
Y: Dysphagia score as a predictor of adverse events due to triplet
chemotherapy and oncological outcomes in 434 consecutive patients
with esophageal cancer. Ann Surg Oncol. 26:4754–4764. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Barker T, Fulde G, Moulton B, Nadauld LD
and Rhodes T: An elevated neutrophil-to-lymphocyte ratio associates
with weight loss and cachexia in cancer. Sci Rep. 10:75352020.
View Article : Google Scholar : PubMed/NCBI
|
